Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Respir Cell Mol Biol ; 60(1): 41-48, 2019 01.
Article in English | MEDLINE | ID: mdl-30130411

ABSTRACT

Severe pulmonary fibrosis such as idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of extracellular matrix and fibroblast activation. Targeting fibroblast activation has contributed to the development of antifibrotic therapeutics for patients with IPF. Mitogen-activated protein kinase-activated protein kinase 2 (MK2), downstream in the transforming growth factor-ß/p38 mitogen-activated protein kinase pathway, has been implicated in inflammatory and fibrosing diseases. Increased concentrations of activated MK2 were expressed in IPF lung and in the mouse bleomycin model of lung fibrosis. The aim of the present study was to determine the role and the mechanisms of MK2 in fibroblast invasion and lung fibrosis. Our results showed that an MK2 inhibitor (MMI-0100) was able to inhibit the invasive capacity of lung fibroblasts isolated from patients with IPF, as well as fibroblasts isolated from both wild-type mice and mice with overexpressing hyaluronan synthase 2 (HAS2) in the myofibroblast compartment. We previously showed that hyaluronan and HAS2 regulate fibroblast invasion and lung fibrosis in vivo. The results of the present study showed that MMI-0100 reduced transforming growth factor-ß-induced hyaluronan production in human and mouse fibroblasts in vitro and that HAS2 mediated MK2 activation, suggesting a feed-forward loop in fibroblast activation. More importantly, MK2 inhibition attenuated hyaluronan accumulation and reduced collagen content in bleomycin-injured mouse lungs in vivo. Conditional deletion of MK2 in fibroblasts attenuated bleomycin-induced lung fibrosis. These data provide evidence that MK2 has a role in fibroblast invasion and fibrosis and may be a novel therapeutic target in pulmonary fibrosis.


Subject(s)
Fibroblasts/pathology , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Peptides/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pulmonary Fibrosis/prevention & control , Severity of Illness Index , Animals , Antibiotics, Antineoplastic/toxicity , Apoptosis/drug effects , Bleomycin/toxicity , Cells, Cultured , Fibroblasts/drug effects , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/metabolism , Pulmonary Fibrosis/pathology
2.
Nat Med ; 22(11): 1285-1293, 2016 11.
Article in English | MEDLINE | ID: mdl-27694932

ABSTRACT

Successful recovery from lung injury requires the repair and regeneration of alveolar epithelial cells to restore the integrity of gas-exchanging regions within the lung and preserve organ function. Improper regeneration of the alveolar epithelium is often associated with severe pulmonary fibrosis, the latter of which involves the recruitment and activation of fibroblasts, as well as matrix accumulation. Type 2 alveolar epithelial cells (AEC2s) are stem cells in the adult lung that contribute to the lung repair process. The mechanisms that regulate AEC2 renewal are incompletely understood. We provide evidence that expression of the innate immune receptor Toll-like receptor 4 (TLR4) and the extracellular matrix glycosaminoglycan hyaluronan (HA) on AEC2s are important for AEC2 renewal, repair of lung injury and limiting the extent of fibrosis. Either deletion of TLR4 or HA synthase 2 in surfactant-protein-C-positive AEC2s leads to impaired renewal capacity, severe fibrosis and mortality. Furthermore, AEC2s from patients with severe pulmonary fibrosis have reduced cell surface HA and impaired renewal capacity, suggesting that HA and TLR4 are key contributors to lung stem cell renewal and that severe pulmonary fibrosis is the result of distal epithelial stem cell failure.


Subject(s)
Alveolar Epithelial Cells/immunology , Cell Self Renewal/immunology , Hyaluronic Acid/metabolism , Lung Injury/immunology , Pulmonary Fibrosis/immunology , Pulmonary Surfactant-Associated Protein C/metabolism , Stem Cells/immunology , Toll-Like Receptor 4/immunology , Alveolar Epithelial Cells/metabolism , Animals , Antibiotics, Antineoplastic/toxicity , Bleomycin/toxicity , Cell Line , Cell Proliferation , Cell Self Renewal/genetics , Flow Cytometry , Glucuronosyltransferase/genetics , Humans , Hyaluronan Synthases , Hydroxyproline/metabolism , Idiopathic Pulmonary Fibrosis/immunology , Idiopathic Pulmonary Fibrosis/metabolism , Idiopathic Pulmonary Fibrosis/pathology , Immunity, Innate , Interleukin-6/immunology , Lung Injury/chemically induced , Lung Injury/metabolism , Mice , Mice, Knockout , Organoids , Pulmonary Fibrosis/metabolism , Pulmonary Fibrosis/pathology , Real-Time Polymerase Chain Reaction , Severity of Illness Index , Stem Cells/metabolism , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL